Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study-Reference-Cited by-同舟云学术

Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study

Published:2020-02-25 Issue:6 Volume:22 Page:978-987
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Munch Marion¹,Meyer Laurent¹^ORCID,Hannedouche Thierry²,Kunz Kristian³,Alenabi Farideh³,Winiszewski Patrice⁴,Baltzinger Philippe¹,Smagala Agnès⁵,Klein Alexandre⁶,Dorey François⁷,Fleury Dominique⁸,Verier‐Mine Odile⁷,Guerci Bruno⁹,Cridlig Joëlle¹⁰,Borot Sophie¹¹,Ducloux Didier¹²,Meyer Nicolas¹³,Hadjadj Samy¹⁴,Chantrel François¹⁵,Kessler Laurence¹¹⁶

Affiliation:

1. CHU Strasbourg, Department of Diabetology Strasbourg Alsace France

2. CHU Strasbourg, Department of Nephrology Strasbourg Alsace France

3. AURAL, Nephrology Strasbourg Alsace France

4. CH Mulhouse, Department of Diabetology Mulhouse, Grand Est France

5. CH Colmar, Department of Diabetology Alsace France

6. CH Colmar, Department of Nephrology Alsace France

7. CH Valenciennes, Department of Diabetology Nord France

8. CH Valenciennes, Department of Nephrology Nord France

9. CHU Nancy, Department of Diabetology Lorraine France

10. CHU Nancy, Department of Nephrology Lorraine France

11. CHU Besançon, Department of Diabetology Franche Comté France

12. CHU Besançon, Department of Nephrology Franche Comté France

13. Strasbourg University Teaching Hospital Federation of Translational Medicine Strasbourg France

14. Department of Diabetology University Hospital of Nantes Nantes France

15. CH Mulhouse, Department of Nephrology Mulhouse, Alsace France

16. INSERM, UMR 1260, Regenerative Nanomedicine University of Strasbourg Strasbourg France

Funder

Novartis

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13988

Reference33 articles.

1. WHO. Global report on diabetes. WHO Library.2016.

2. Validation of comorbid conditions on the end‐stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD;Longenecker JC;J Am Soc Nephrol.,2000

3. Type 2 diabetes in patients with end‐stage kidney disease: influence on cardiovascular disease‐related mortality risk

4. Complications of Diabetes 2016

5. Glycemic Control and Cardiovascular Mortality in Hemodialysis Patients With Diabetes

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus;Cureus;2023-10-17

2. Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review;Cureus;2023-05-18

3. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials;Frontiers in Endocrinology;2022-10-24

4. Dipeptidyl peptidase‐4 inhibitor and insulin combination treatment in type 2 diabetes and chronic kidney disease: A meta‐analysis;Journal of Diabetes Investigation;2021-10-20

5. CORRELATION STUDY OF SERUM GLYCOSYLATED ALBUMIN LEVEL, ERAGE LEVEL REDUCTION AND CORONARY ARTERY CALCIFICATION AND REMODELING IN PATIENTS OF TYPE 2 DIABETES: AN INTRAVASCULAR ULTRASOUND STUDY;ACTA MEDICA MEDITERR;2021